Consistent with the necessity for dual inhibition of functionally redundant pro-survival BH3 family members BCL-2 and MCL-1, combined administration of voruciclib and venetoclax resulted in significantly enhanced tumor growth inhibition compared to either single agent alone, in two distinct xenograft models of ABC DLBCL. Here, MCL1 is linked to diffuse large B-cell lymphoma.